AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05370911
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first oral dose will be 25 mg, and the second dose will be either 25 mg or 30 mg, depending on response to first dose.~Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic. We will use synthetically produced oral psilocybin in this study.~Other Names:~Magic Mushrooms
Trial: NCT05275023
Drug: JNJ-73763989
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-73763989 will be administered subcutaneously.
Trial: NCT05275023
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor will be administered as IV infusion.
Trial: NCT05275023
Drug: Tenofovir Disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil film-coated tablets will be administered orally.
Trial: NCT05275023
Drug: Tenofovir Alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TAF film-coated tablets will be administered orally.
Trial: NCT05275023
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETV film-coated tablets will be administered orally.
Trial: NCT05447663
Drug: Siremadlin
RxNorm normalized name: Siremadlin
DrugBank: Siremadlin (DB16331)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siremadlin was administered at a starting dose of 30 mg/day on days 1-5 of a 28-day treatment cycle (Part 1).
Trial: NCT05536752
Drug: QA102
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT04732598
Drug: Paclitaxel + bevacizumab therapy
RxNorm normalized name: Paclitaxel
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV
Trial: NCT04732598
Drug: Paclitaxel + bevacizumab + atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Atezolizumab\] 840 mg/body, day 1,15, IV \[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV
Trial: NCT05603741
Drug: 0.9% Sodium Chloride Injection
RxNorm normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will be injected subcutaneously with a single 0.5ml dose
Trial: NCT05603741
Drug: Lidocaine Injection 2%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will be injected subcutaneously with a single 0.5ml dose
Trial: NCT06047548
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06042855
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
Trial: NCT05661357
Drug: Disitamab Vedotin Combined With Fruquintinib
RxNorm normalized name: Disitamab vedotin
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furquinotinib: 3mg, Qd, 28 days as a cycle. Vidicizumab: according to the instructions of Vidicizumab, d1, 2.5 mg/kg, intravenous drip (ivgtt)
Trial: NCT05146154
Drug: Imipenem/Cilastatin/Relebactam 1.25g
DrugBank: Cilastatin (DB01597)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Imipenem/cilastatin/relebactam is a combination beta-lactam/beta-lactamase inhibitor antimicrobial marketed under the brand name Recarbrio and the approved dose is 1.25g Q6h in patients with normal renal function. The individual components of this agent must be administered together and cannot be separated. Therefore, this constitutes only one intervention. Each subject will receive at least 2 doses of study drug.
Trial: NCT05494411
Drug: Mitomycin for pyelocalyceal solution
RxNorm normalized name: mitomycin Powder for Pyelocalyceal Solution
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06264310
Drug: R2R01
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
Trial: NCT05581875
Drug: Belantamab Mafodotin-Blmf
RxNorm normalized name: belantamab mafodotin-blmf
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes
Trial: NCT05581875
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
Trial: NCT05581875
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide will be administered per os.
Trial: NCT05581875
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered intravenously or per os.
Trial: NCT05302648
Drug: Human Derived anti-BCMA CAR-T Injection
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous genetically modified anti-BCMA CAR transduced T cells
Trial: NCT06660368
Drug: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completion of cladribine, and mitoxantrone 16 mg/m2 given intravenously over 30 minutes for 3 days (days 1-3) after completion of cytarabine.
Trial: NCT06660368
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax will be administered orally, once daily, with food.
Trial: NCT05774639
Drug: Omalizumab Injection
RxNorm normalized name: omalizumab Injection
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)
Trial: NCT04807140
Drug: Toripalimab, nab-paclitaxel, carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive Toripalimab IV on day 1, nab-paclitaxel IV on day 1 and carboplatin IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT04807140
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Toripalimab IV on day 1.~Treatment repeats every 21 days for up to 2-4 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT06117046
Drug: 50 ml of normal saline intravenous infusion
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 ml of normal saline intravenous infusion
Trial: NCT05098613
Drug: CD19x22 CAR T Cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.
Trial: NCT04527380
Drug: Ixekizumab
RxNorm normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT04527380
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT04910152
Drug: BRD4 Inhibitor PLX51107
RxNorm normalized name: Brd4 inhibitor plx51107
DrugBank: PLX51107 (DB17543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04829695
Drug: Artesunate-amodiaquine drug combination
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artesunate-amodiaquine is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.
Trial: NCT04777838
Drug: Citalopram 10 MG
RxNorm normalized name: citalopram 10 MG
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg of citalopram every day
Trial: NCT04777838
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg of Amitriptyline every
Trial: NCT05172570
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin is a common medication used preoperatively and postoperatively as part of multimodal analgesia to help with acute pain.
Trial: NCT05848687
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
Trial: NCT05848687
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05848687
Drug: PEG asparaginase
RxNorm normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05848687
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT05848687
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken PO or NG
Trial: NCT05848687
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Will be administered at 15 mcg/m2/day for 28 days following induction and reinduction
Trial: NCT05848687
Drug: Ziftomenib
RxNorm normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3+3 dose escalation will be done. Dose level 1 will start at 75% of the adult recommended phase two dosing which has been established in phase I studies. Based on tolerability, we will either de-escalate to 50% RP2D (dose level -1) or escalate to 100% RP2D
Trial: NCT05729568
Drug: Teropavimab
RxNorm normalized name: Teropavimab
DrugBank: Teropavimab (DB18916)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05729568
Drug: Zinlirvimab
RxNorm normalized name: Zinlirvimab
DrugBank: Zinlirvimab (DB18867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05729568
Drug: Lenacapavir Tablet
RxNorm normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05729568
Drug: Lenacapavir Injection
RxNorm normalized name: lenacapavir Injection
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT06503042
Drug: Chemotherapy combined with immunotherapy
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the chemotherapy combined with immunotherapy group use any chemotherapy drug in combination with any immunotherapy drug. The premise is that the treatment regimen for patients is consistent with the diagnostic and treatment protocols.
Trial: NCT06111781
Drug: Relugolix 120 MG [Orgovyx]
RxNorm normalized name: relugolix 120 MG [Orgovyx]
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ORGOVYX will be initiated with a loading dose of 360 mg on the first day and continue treatment with a 120 mg dose taken orally once daily at approximately the same time each day. Total length of treatment will be 30 days.
Trial: NCT06343935
Drug: Linperlisib
RxNorm normalized name: Linperlisib
DrugBank: Linperlisib (DB17235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linperlisib is a small molecule inhibitor of phosphoinositol 3-kinase-δ (PI3K-δ)
Trial: NCT06427395
Drug: Saroglitazar Magnesium 1 mg
RxNorm normalized name: pitavastatin magnesium 1 MG
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program
Trial: NCT05065372
Drug: Metformin Hcl 1000Mg Tab
RxNorm normalized name: METFORMIN HCL 1000MG TAB
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Agent used to modify insulin sensitivity
Trial: NCT05065372
Drug: Aminohippurate Sodium 20 % Injection
RxNorm normalized name: aminohippurate sodium 20 % Injection
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
Trial: NCT05065372
Drug: Iohexol 300 Mg/mL Injectable Solution
RxNorm normalized name: iohexol 300 mg/mL injectable solution
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diagnostic aid/agent used to measure glomerular filtration rate
Trial: NCT06448143
Drug: Indigotindisulfonate sodium 0.8% injection
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental contrast dye for diagnostic procedures, commonly used as a visualization aid in pelvic and abdominal surgeries, as well as for evaluating ureteral patency.
Trial: NCT05685602
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05685602
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT06311682
Drug: Tralokinumab + TCS
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.
Trial: NCT05714683
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
Trial: NCT05968599
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As provided in real-world setting
Trial: NCT05968599
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As provided in real-world setting
Trial: NCT06062745
Drug: 18F-fluciclovine
RxNorm normalized name: fluciclovine (18F)
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 18F-fluciclovine is a radiotracer targeting amino-acid transporters.Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance to make images of processes that are happening in the body
Trial: NCT04438213
Drug: Ertugliflozin
RxNorm normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Trial: NCT04438213
Drug: Metolazone
RxNorm normalized name: Metolazone
DrugBank: Metolazone (DB00524)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
Trial: NCT05222971
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1,500 mg IV on Day 1~Every 4 weeks
Trial: NCT05222971
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg twice daily~Every 4 weeks
Trial: NCT04616027
Drug: PF-06882961 20 mg
RxNorm normalized name: cytarabine
DrugBank: PF-06882961 (DB16043)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
Trial: NCT06427330
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. st dose is given after D+60：inotuzumab 0.3mg/m2~2. nd dose is given after 1 month：inotuzumab 0.6mg/m2
Trial: NCT06550271
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rapamycin in 2 different dosage forms (compounded and generic)
Trial: NCT06441045
Drug: Double Dose of Third-generation EGFR-TKI
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double Dose of Third-generation EGFR-TKI
Trial: NCT06441045
Drug: Intrathecal Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intrathecal Pemetrexed
Trial: NCT06278402
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tofacitinib 5mg twice daily for treatment of alopecia areata, totalis and universalis.
Trial: NCT06338683
Drug: Olanzapine 2.5 MG
RxNorm normalized name: olanzapine 2.5 MG
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral olanzapine 2.5 mg once daily at bedtime until disease progression
Trial: NCT06338683
Drug: Standard anti-tumor treatment
RxNorm normalized name: G 1 (anti-tumor agent)
DrugBank: LNS-8801 (DB18091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinicians choose the appropriate standard antitumor drug therapy based on the patient's specific situation
Trial: NCT05239546
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive Dostarlimab 500 mg IV every 3 weeks for 9 cycles followed by 1000 mg every 6 weeks for 12 cycles until 2 years
Trial: NCT06177041
Drug: M108 monoclonal antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion.
Trial: NCT06177041
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin will be administered as a 2-hour IV infusion.
Trial: NCT06370273
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg once daily via oral ingestion
Trial: NCT06370273
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2.5mg twice daily via oral ingestion
Trial: NCT06370273
Drug: Enoxaparin Injectable Solution
RxNorm normalized name: enoxaparin Injectable Solution
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg once daily via subcutaneous injection
Trial: NCT06370273
Drug: Tinzaparin Injectable Solution
RxNorm normalized name: tinzaparin Injectable Solution
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4500 IU once daily via subcutaneous injection
Trial: NCT06370273
Drug: Dalteparin Injectable Solution
RxNorm normalized name: dalteparin Injectable Solution
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU once daily via subcutaneous injection
Trial: NCT06370273
Drug: Fondaparinux Injectable Product
RxNorm normalized name: fondaparinux Injectable Product
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg once daily via subcutaneous injection
Trial: NCT05266027
Drug: Nalbuphine Sebacate (Naldebain)
RxNorm normalized name: sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine Sebacate (Naldebain) 2mL/150mg would be intramuscularly injected during knee arthroplasty surgery.